Investments
In addition to providing CMC consultancy services, Phase2Phase re-invest its profit in early-stage Life Science Ventures. Phase2Phase investments are made separately or as part of an investor network.
Phase2Phase investments are presented below:
Status: Active investment, company listed in April, 2021
Lipum develops a safer and more efficacious treatment of chronic inflammatory diseases to satisfy unmet medical needs for millions of people.
Status: Active investment, privately held company
Genagon develops a unique ADC (Antibody-Drug Conjugate), targeting the tumors’ microenvironment where the target accumulates only on the surface of cells within the tumor and is rapidly internalized, enabling targeting with low risk of side-effects.
Status: Discontinued investment
Athera was a biopharmaceutical company with focus on developing targeted anti-inflamatory biological drugs for treatment of cardiovascular disease.
Status: Active investment, privately held company
Stoaf III SciTech is a fund organized as a Limited Partnership, investing in the areas of Life Science, Advanced Industrial Technologies, Advanced ICT and Sustainable Energy Technologies.
Status: Active investment, privately held company
Moligo Technologies has developed a technology for Enzymatic production of LONG and ultra-PURE ssDNA at industrial SCALE.
Status: Active investment, privately held company
PharmNovo aims to improve people’s quality of life through development of an innovative, sustainable and effective medcinal product targeting chronic pain.
Status: Active investment, privately held company
LSI Alpha is a venture fund, organized as a Limited Partnership, with focus on Life Science. LSI Alpha was founded in 2020 by Life Science Invest and has more than 20 partners and has invested in seven Life Science start-ups.
Status: Active investment, privately held company
Synartro is a Swedish life science company developing a drug for the treatment of knee OA (Osteoarthritis).
By combining Synartro’s novel delivery technology with existing proven drugs, Synatro aims to provide superior and sustained efficacy without systemic side-effects
Status: Active investment, privately held company
Neogap’s pharmaceutical product, pTTL – Personalised Tumour Trained Lymphocytes, provides a unique personalised cell therapy designed to very precisely target and eliminate cancer in a personalised setting, with comparably mild side effects
Status: Active investment, privately held company
Vakona develops a new, antibiotic-free treatment for inflammatory acne vulgaris. Vakona’s product is a natural bacterial enzyme that degrades the bacterial biofilm to open up blocked hair follicles.
Status: Active investment, privately held company
LSI Beta is a venture fund, organized as a Limited Partnership, with focus on Life Science. LSI Beta was founded in 2021/2022 by Life Science Invest and has more has invested in seven Life Science start-ups.
Status: Active investment, privately held company
Key2Brain is a Swedish biotechnology company committed to developing a novel and efficacious platform technology, enabling brain acess to biopharmaceuticals.
Status: Active investment, privately held company
Disruptive Pharma is a pharmaceutical company developing novel drug products and drug formulations.
Status: Active investment, privately held company
AAX Biotech AB is a startup focusing on antibody technologies; ”Seqitope” provides improved antibody characterization through high resolution, high throughput epitope mapping and ”Opti-mAb” consists of a new scFv antibody format.
Status: Active investment, privately held company
Akiram Therapeutics develops next generation radiopharmaceuticals to specifically and efficiently visualize and treat solid cancers